Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03152448 · ClinicalTrials.gov registry record
Prospective Prolaris Value and Efficacy
A clinical trial, sponsored by Myriad Genetic Laboratories.
- Terminated
- Registry status
- 1,511
- Enrollment target
NCT03152448: Clinical Trial study, sponsored by Myriad Genetic Laboratories.
NCT03152448 is a clinical trial that was terminated before completion, run by Myriad Genetic Laboratories. The registered enrollment target is 1,511 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03152448 was terminated before completion, sponsored by Myriad Genetic Laboratories.
- TERMINATED
- Registry status
- 1,511 participants
- Enrollment target
Study Summary
This is a prospective study to measure the impact on first-line therapy of genomic testing of biopsy tissue from recently diagnosed treatment-naïve patients with early stage localized prostate cancer.
Primary Outcome
Comparison of percentage change from the Pre-Prolaris test treatment option (based on standard clinical pathological parameters) versus the actual treatment option implemented following results of Prolaris
Interventions
- BEHAVIORAL Prolaris
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,511 participants |
| Start Date | 2015-09-01 |
| Est. Completion | 2022-03-21 |
Why NCT03152448 stopped before completion
NCT03152448 is an observational study that tracks outcomes without assigning an intervention. Its 1,511 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Prolaris is the first listed.
NCT03152448 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03152448 about?
NCT03152448 is a clinical study titled "Prospective Prolaris Value and Efficacy". This is a prospective study to measure the impact on first-line therapy of genomic testing of biopsy tissue from recently diagnosed treatment-naïve patients with early stage localized prostate cancer.
What is the current status of trial NCT03152448?
This trial is currently terminated. The enrollment target is 1,511 participants. The study started on 2015-09-01. Estimated completion is 2022-03-21.
What interventions are being tested in trial NCT03152448?
The interventions under investigation include: Prolaris (BEHAVIORAL).
Who is sponsoring clinical trial NCT03152448?
This trial is sponsored by Myriad Genetic Laboratories, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07136623 · 1,513 participants
Detecting Pulmonary Hypertension With the Eko CORE 500 Digital Stethoscope
- NCT05633654 · 1,514 participants · Phase 3
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- NCT07232017 · 1,520 participants
Implementation of Intensive Hypertension Management Approaches: Cleveland Clinic
- NCT00178724 · 1,500 participants
Spinal Cord Injury Registry - North American Clinical Trials Network
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI